Department of Clinical Laboratory, The Second Hospital of Shandong University, Jinan 250033, China.
Shandong Provincial Clinical Medicine Research Center for Clinical Laboratory, Jinan 250033, China.
ACS Nano. 2023 Sep 12;17(17):16553-16564. doi: 10.1021/acsnano.3c02148. Epub 2023 Aug 1.
Gastric cancer (GC) is one of the most common tumors worldwide and is the leading cause of tumor-related mortality. Traditional biomarkers and screening methods cannot meet the clinical demands. There is an urgent need for highly sensitive diagnostic markers as well as accurate quantification methods for early gastric cancer (EGC) screening. Here a dual-target cooperatively responsive fluorescent nanomachine by the innovative application of two targets─responsive strand migration system with a single-amplification-cycle element was developed for the simultaneous detection of GC biomarkers miR-5585-5p and PLS3 mRNA, which were selected by next-generation sequencing and RT-qPCR. It was also an RNA extraction-free, PCR-free, and nonenzymatic biosensor to achieve tumor cell imaging and serum diagnosis. Requiring only a 20 μL serum sample and 20 min incubation time, the nanomachine achieved an ultrasensitive detection limit of fM level with a broad linear range from fM to nM. More importantly, a higher AUC value (0.884) compared to the clinically used biomarker CA 72-4 was obtained by the nanomachine to distinguish GC patients successfully. Notably, for the key concerns of diagnosis of EGC patients, the nanomachine also achieved a satisfactory AUC value of 0.859. Taken together, this work has screened and obtained multiple biomarkers and developed a fluorescent nanomachine for combination diagnosis of GC, providing an ingenious design of a functionalized DNA nanomachine and a feasible strategy for the transformation of serum biomarkers into clinical diagnosis.
胃癌(GC)是全球最常见的肿瘤之一,也是肿瘤相关死亡的主要原因。传统的生物标志物和筛选方法无法满足临床需求。因此,迫切需要高度敏感的诊断标志物以及用于早期胃癌(EGC)筛查的准确定量方法。在这里,通过创新应用具有单扩增周期元件的反应性链迁移系统,开发了一种双靶协同响应的荧光纳米机器,用于同时检测 GC 生物标志物 miR-5585-5p 和 PLS3 mRNA。这两种标志物是通过下一代测序和 RT-qPCR 选择的。该纳米机器还实现了无 RNA 提取、无 PCR 和无酶的生物传感器,可用于肿瘤细胞成像和血清诊断。该纳米机器仅需 20 μL 血清样本和 20 min 孵育时间,即可达到 fM 级别的超灵敏检测限,并具有从 fM 到 nM 的宽线性范围。更重要的是,与临床使用的生物标志物 CA 72-4 相比,该纳米机器获得了更高的 AUC 值(0.884),可成功区分 GC 患者。值得注意的是,对于 EGC 患者诊断的关键关注点,该纳米机器也实现了令人满意的 AUC 值 0.859。总之,这项工作筛选并获得了多种生物标志物,并开发了用于 GC 联合诊断的荧光纳米机器,为功能化 DNA 纳米机器的设计提供了新颖的思路,并为将血清生物标志物转化为临床诊断提供了可行的策略。